Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OK-201
- Development stage
- Discontinued
- Lead developer
- OKYO Pharma
- Modality
- Small Molecules, Peptides
- Administration
- Topical, Ophthalmic
01
Overview
OK-201 is a synthetic peptide and non-opioid analgesic developed by OKYO Pharma for the treatment of neuropathic and ocular pain. It acts as an agonist of human MAS-related G protein-coupled receptor X1 (MRGPRX1), a member of the G protein-coupled receptor family involved in pain signaling pathways. Preclinical studies demonstrated that topical administration of OK-201 reduced corneal pain responses in animal models to levels comparable with gabapentin, suggesting potential utility for acute and chronic ocular pain. Despite promising preclinical results, development was discontinued in favor of other candidates[1][3][6].
- Other names
- BAM8 analogueBAM-8 analogueBAM 8 analogue
02
Targets
MRGPRX1 (Mas-related G protein-coupled receptor X1)
Beyond the preview
Go deeper on OK-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OK-201.